Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765851 · ClinicalTrials.gov registry record · Phase 1
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Advanced Solid Tumor, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 8
- Study locations
NCT05765851: Active Phase 1 study of Breast Cancer and Advanced Solid Tumor, sponsored by Daiichi Sankyo.
NCT05765851 is a Phase 1 study of Breast Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 78 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05765851, a Phase 1 study of Breast Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG T-DXd
- DRUG DS-1103a
Study Locations (8)
Other
- Princess Margaret Cancer Centre, University Health Network - Toronto
- Hospital Universitari Vall d'Hebron - Barcelona
Florida
- Florida Cancer Specialists - Sarasota
Rhode Island
- Lifespan Cancer Institute - Providence
Utah
- University of Utah - Salt Lake City
Virginia
- NEXT Oncology - Fairfax
Haute Garonne
- Oncopole - Institut Claudius Regaud - Toulouse
Rhone
- Centre Léon Bérard - Lyon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT05765851 still lists
NCT05765851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which T-DXd is the first listed.
NCT05765851 lists 8 locations in 7 states (Other, Florida, Rhode Island).
Frequently Asked Questions
What is clinical trial NCT05765851 about?
NCT05765851 is a clinical study titled "A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors". This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
What is the current status of trial NCT05765851?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2023-05-30. Estimated completion is 2026-06-30.
What conditions does trial NCT05765851 study?
This clinical trial studies the following conditions: Breast Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT05765851?
The interventions under investigation include: T-DXd (DRUG), DS-1103a (DRUG).
Who is sponsoring clinical trial NCT05765851?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05765851 being conducted?
This trial has 8 study locations across Florida, Rhode Island, Utah, Virginia, Haute Garonne. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05765851's enrollment target sits among peer trials
78 662nd of 1224 higher than 556 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI